… This phase II trial assessed efficacy and safety of fruquintinib in combination with gefitinib,
in patients with advanced non-small cell lung cancer (NSCLC). …

… This study shows that furmonertinib was superior to gefitinib in terms of progression-free
survival as first-line treatment for Chinese patients with EGFR mutation-positive NSCLC. This …

… as first-line therapy significantly improved PFS and led to a trend for prolonged OS compared
with gefitinib … growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer …

… who have diabetes with non–small cell lung cancer (NSCLC) to EGFR tyrosine kinase
inhibitors (TKIs). We therefore examined its effects in combination with gefitinib in patients without …

… This phase II trial examines the efficacy of neoadjuvant gefitinib in patients with clinically …
EGFR-TKIs has been used as first-line therapies in advanced EGFR-mutant NSCLC, but there …

… ACTIVE is the first phase 3 study conducted in the People’s Republic of China … factor receptor
2 tyrosine kinase inhibitor, plus gefitinib as first-line therapy in … Non–small cell lung cancer …

… A single-arm phase II trial, the BELIEF study, demonstrated a 1-year PFS of 55.6%, with a …
phase II study (JO25567) evaluated bevacizumab plus erlotinib in patients with stage IIIB/IV or …

… standard care for advanced non–small cell lung cancer (NSCLC… Recently, a similar phase II
trial that demonstrated first-line … re-challenge with gefitinib after first-line treatment with EGFR-…

… In conclusion, the OS benefit from first-line treatment with dacomitinib versus gefitinib
was maintained after extended follow-up in patients with advanced NSCLC with EGFR-activating …

… This double-blind phase III trial evaluated the efficacy and safety of … with gefitinib as a
first-line treatment for locally advanced or metastatic EGFR-mutated non–small-cell lung cancer (…